Park Edge Advisors LLC Sells 826 Shares of Bristol-Myers Squibb (NYSE:BMY)

Park Edge Advisors LLC trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.9% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 15,877 shares of the biopharmaceutical company’s stock after selling 826 shares during the quarter. Park Edge Advisors LLC’s holdings in Bristol-Myers Squibb were worth $861,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $34,000. VisionPoint Advisory Group LLC lifted its holdings in shares of Bristol-Myers Squibb by 300.5% in the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 553 shares in the last quarter. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $40,000. Finally, Wetzel Investment Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $40,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Trading Down 1.0 %

Shares of NYSE BMY traded down $0.39 during mid-day trading on Thursday, reaching $40.06. The company had a trading volume of 9,131,450 shares, compared to its average volume of 16,023,750. The business’s 50-day moving average is $42.46 and its 200-day moving average is $47.91. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The stock has a market cap of $81.21 billion, a price-to-earnings ratio of -12.92, a price-to-earnings-growth ratio of 13.84 and a beta of 0.44. Bristol-Myers Squibb has a 52 week low of $39.63 and a 52 week high of $65.38.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same period in the prior year, the business earned $2.05 EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.99%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BMY. Barclays decreased their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Wells Fargo & Company upped their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, BMO Capital Markets reduced their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.